Skip to content
Open access · CC-BY via OpenAlex

The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials

Jeffrey L. Cummings

Alzheimer s & Dementia · 2018 · ▲ 138 citations

Abstract

INTRODUCTION: The National Institute on Aging-Alzheimer's Association Research Framework on Alzheimer's disease (AD) represents an important advance in the biological characterization of the AD spectrum. METHODS: The National Institute on Aging-Alzheimer's Association Framework is considered as it applies to clinical trials. RESULTS: Using the combination of amyloid (A), tau (T), and neurodegeneration (N) biomarkers, the Framework provides a means of defining the state of patients with regard to Alzheimer pathologic change. The Framework is relevant to clinical trials of disease-modifying agents, allowing participants to be characterized biologically at baseline. The ATN Framework can also inform trial outcomes. The preclinical phase of the disease after amyloid deposition is defined by A+T-N-, and the transition to prodromal disease and dementia is characterized by the addition of T and N. Most symptomatic patients in clinical trials are in the class of A+T+N- and A+T+N+. DISCUSSION: The National Institute on Aging-Alzheimer's Association Framework on AD represents progress in providing biomarker profiles of participants in the AD spectrum that can be used to help design clinical trials.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.jalz.2018.05.006
Canonical
link ↗
Fetched
2026-10-16 MST

Cite this

APA
Cummings, J.L. (2018). The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. <em>Alzheimer s & Dementia</em>. https://doi.org/10.1016/j.jalz.2018.05.006
Vancouver
Cummings JL. The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimer s & Dementia. 2018. doi:10.1016/j.jalz.2018.05.006.
BibTeX
@article{jeffrey2018TheNat, title = {The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials}, author = {Jeffrey L. Cummings}, journal = {Alzheimer s & Dementia}, year = {2018}, doi = {10.1016/j.jalz.2018.05.006}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings